IP Library › Granted Patent US 12697369
Granted Patent B2
US 12697369 · App. 17/428,769 · Granted Aug 4, 2026

Targeting CD24-Siglec interactions for the treatment of nonviral hepatitis and liver fibrosis

Inventors: Yang Liu (Washington, DC); Pan Zheng (Washington, DC); Xu Wang (Washington, DC); Mingyue Liu (Washington, DC); Martin Devenport (Gaithersburg, MD)
Assignees: ONCOIMMUNE, INC.; UNIVERSITY OF MARYLAND, BALTIMORE
A61K38/177A61K38/1774A61K47/6811A61P1/16A61P3/04C07K14/70596C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697369
App. No.
17/428,769
Filed
Aug 5, 2021
Granted
Aug 4, 2026
Kind
B2
Art Unit
1647
USPC
424/178.1
Abstract

Provided herein are methods and compositions for the prevention and treatment of nonalcoholic steatohepatitis (NASH) by targeting the CD24-Siglec axis.

Claims (22)

1 . A method of treating nonviral hepatitis in a subject in need thereof, comprising administering a CD24 protein to the subject.

2 . The method of claim 1 , wherein the CD24 protein comprises a mature human CD24 polypeptide.

3 . The method of claim 2 , wherein the mature human CD24 polypeptide comprises the sequence set forth in SEQ ID NO: 1 or 2.

4 . The method of claim 3 , wherein the CD24 protein comprises a Fc region of a mammalian Ig protein fused at the N-terminus or C-terminus of the CD24 protein.

5 . The method of claim 4 , wherein the Ig protein is a human Ig protein.

6 . The method of claim 5 , wherein the Fc region comprises the hinge region and CH2 and CH3 domains of IgG1, IgG2, IgG3, IgG4, or IgA.

7 . The method of claim 6 , wherein the CD24 protein comprises the sequence set forth in SEQ ID NO: 6, 11, or 12.

8 . The method of claim 7 , wherein the amino acid sequence of the CD24 protein consists of the sequence set forth in SEQ ID NO: 6, 11, or 12.

9 . The method of claim 5 , wherein the Fc region comprises the hinge region and CH2, CH3 and CH4 domains of IgM.

10 . The method of claim 1 , wherein the CD24 protein is soluble.

11 . The method of claim 1 , wherein the CD24 protein is glycosylated.

12 . A method of treating liver fibrosis in a subject in need thereof, wherein the subject does not have a history of excessive alcohol use, comprising administering a CD24 protein to the subject.

13 . The method of claim 12 , wherein the CD24 protein comprises a mature human CD24 polypeptide.

14 . The method of claim 13 , wherein the mature human CD24 polypeptide comprises the sequence set forth in SEQ ID NO: 1 or 2.

15 . The method of claim 14 , wherein the CD24 protein comprises a Fc region of a mammalian Ig protein fused at the N-terminus or C-terminus of the CD24 protein.

16 . The method of claim 15 , wherein the Ig protein is a human Ig protein.

17 . The method of claim 16 , wherein the Fc region comprises the hinge region and CH2 and CH3 domains of IgG1, IgG2, IgG3, IgG4, or IgA.

18 . The method of claim 17 , wherein the CD24 protein comprises the sequence set forth in SEQ ID NO: 6, 11, or 12.

19 . The method of claim 18 , wherein the amino acid sequence of the CD24 protein consists of the sequence set forth in SEQ ID NO: 6, 11, or 12.

20 . The method of claim 16 , wherein the Fc region comprises the hinge region and CH2, CH3 and CH4 domains of IgM.

21 . The method of claim 12 , wherein the CD24 protein is soluble.

22 . The method of claim 12 , wherein the CD24 protein is glycosylated.